Pfizer Inc (PFE) Options

PFE back in the $30s :)

What created Hemophilia-A

Why does it exist

PFE GT for Hemophilia-A meets phase-3 endpoints:

https://finance.yahoo.com/news/pfizer-announces-positive-topline-results-104500301.html The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment. Following a single 3e13 vg/kg dose, giroctocogene fitelparvovec demonstrated a statistically significant reduction in mean total ABR compared to the pre-infusion period (1.24 vs 4.73; one-sided p-value=0.0040).

Key secondary endpoints as defined by the trial protocol were met and also demonstrated superiority compared to prophylaxis. 84% of participants maintained FVIII activity >5% at 15 months post-infusion (one-sided p-value = 0.0086) with the majority of participants having FVIII activity ≥15%, and the mean treated ABR showed a statistically significant 98.3% reduction from 4.08 in the pre-infusion period to 0.07 post-infusion (from Week 12 up to at least 15 months [15-44 months]; one-sided p-value < 0.0001). Throughout the study, among all dosed participants, one participant (1.3%) returned to prophylaxis post-infusion. BMRN has an FDA-approved GT for hemophilia-A called Roctavian (#msg-172243819), but the sales to date have been de minimis (#msg-173910310).

Note: PFE’s giroctocogene fitelparvovec for hemophilia-A should not be confused with Beqvez, PFE’s FDA-approved GT for hemophilia-B (#msg-174309616).

Zacks' Research Report on Pfizer,...
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

"from where I'm looking, the world is flat." NO VAX LOL

Sangamo Therapeutics (NASDAQ: SGMO) and Pfizer (NYSE: PFE) have reported positive Phase 3 results for giroctocogene fitelparvovec, a gene therapy for hemophilia A. The AFFINE trial met its primary and key secondary objectives, demonstrating superiority over routine Factor VIII replacement therapy in reducing annualized bleeding rates. A single dose of the therapy significantly reduced mean total ABR from 4.73 to 1.24, with 84% of participants maintaining Factor VIII activity >5% at 15 months post-infusion. The therapy was generally well-tolerated. Sangamo is eligible for substantial milestone payments and royalties if the therapy is approved and commercialized. Pfizer plans to discuss the data with regulatory authorities soon.

Must have been a weaker version

Testing

Isn't what it used to be
Tenth day of Paxlovid (not tenth course) Keep on keeping on

Until the dose

Is done

Tenth day of Paxlovid (not tenth course).

President Biden finished his 10th course of Paxlovid today; symptoms have resolved “almost completely,” update from his physician says:

https://www.whitehouse.gov/wp-content/uploads/2024/07/Letter7.22.2024.pdf

Once we get closer to NOV 2024 PFE going to start inching up will see high 35sss plus

Trump 2024 !!!

https://www.whitehouse.gov/wp-content/uploads/2024/07/Letter-7.21.24.pdf

How does one know this

What test was used

Why Paxlovid

President Biden tests positive for Covid with mild symptoms, per White House, and has received first dose of Paxlovid

It's a mind thing

Without having to think

Giving Planned Obsolescence a new replacement.

The basic premise of wellness

Is being turned on its head

Perception of wellness

While making one sick

No need to worry

Have something for that

Another form of

Predictive programming

https://mypatriotsnetwork.com/big-pharma-protections-under-attack-as-americans-fight-back/?utm_name=Id

I was hoping it would dip to 22 and would have bot a few to flip. I think it will probably climb but there are head winds and lots of analysts are doubting the latest strategies.

for certain. will be waiting.

What happens when the scam is revealed

Totally against the grain

But true

I agree 1000%

Stock Dividend $$$$$$$$$

good news from their latest acquisition, or the accretive benefits of it or a dividend hike or stock buyback announcement

also a safe haven money rotation play as rates come down a little

PFE has been one of the worst trading stocks in months, i think it truly bottomed out

$25-27 was a great buy area imo

What is the control mechanism

That makes it so

if UNH can surge $33 in one day, PFE can surge $2-$4 in one day

It has been a year since that happened. I predicted this climb which is why I covered my shorts. 35 would be a good place to short again but most likely there will be set backs before reaching it. Bares watching,,, or should I say bears watching. Too bad this isn't an honest company.

Still trying to figure out

What is wrong with

The human immune system

Where it would need

So much help

Poisoning aside

PFE going back to $35

Us and Them

Pink Floyd

THE WRITING IS ON THE WALL

Rather than cite

It would be nice

To give an explanation

Have any of one's own words

To go behind what one posts

Curious

If you are long....why? Ok, I get it. But to continue is rubber stamping the company that killed your family and fellow citizens of the world.
Even Redfield finally admits it. "Redfield went further, admitting that the spike protein produced by mRNA vaccines is “toxic to the body” and triggers “a very strong pro-inflammatory response.”

https://childrenshealthdefense.org/defender/robert-redfield-mrna-covid-vaccine-risk/?utm_id=20240712

Well maybe https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering?oly_enc_id=4924G0643390I0A

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.biospace.com/article/pfizer-moves-forward-with-obesity-pill-plans-dose-optimization-studies-this-year/

May the space
Be with you

“Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several preclinical candidates," said Pfizer's chief scientific officer, Mikael Dolsten.

"The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space."

The patent lawsuit in Germany will chop Pfizer down to size if this doesn't work out in their favor. This bears paying close attention.

For what ails humanity

Proverbial

Hamster wheel

Until a cure

With what they've got

Keep on running

While adding on

Never ending cycle

None of it is good

TÜBINGEN, Germany/BOSTON, USA – July 11, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.



The U.S. trial against Pfizer/BioNTech will take place on March 3, 2025, before the U.S. District Court of the Eastern District of Virginia. A previously issued court recommendation to stay the proceedings for all 10 U.S. patents was withdrawn. The recommendation had followed a motion by Acuitas Therapeutics to intervene, sever and stay proceedings based on co-owner and co-inventorship claims. It was resolved after both companies reached a settlement in April 2024, which provided Acuitas licenses to several patents, including three out of four disputed U.S. patents. These three patents have been withdrawn from the U.S. patent litigation against Pfizer/BioNTech. In return, Acuitas acknowledges that CureVac is the sole owner of the disputed patents.



Litigation in Europe will continue March 25, 2025, with a hearing on the validity of EP 3 708 668 B1 (split poly-A tail technology), before the Opposition Division of the European Patent Office. The infringement action in relation to this patent was previously suspended pending the validity determination by the European Patent Office. In the German patent litigation against Pfizer/BioNTech, the settlement with Acuitas Therapeutics led to the withdrawal of two utility models covering equivalent claims to the three patents withdrawn in the United States. As previously announced, a hearing before the infringement court of Düsseldorf covering the European patent EP 4 023 755 B1 (split poly-A tail technology) and the utility model DE 20 2021 004 130 U1 (COVID-19 vaccine design), is scheduled for September 10, 2024.



Furthermore, a trial in the UK has started on July 10, 2024. It is based on a declaration of non-infringement and request for revocation by Pfizer/BioNTech in the UK for the two CureVac patents EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A-tail technology). CureVac counterclaimed for infringement. A judgement is expected later in 2024. The trial for the further involved patent EP 1 857 122 B1 (G/C enrichment technology) will be set for a later time point.

I hope the oral version has better efficacy than the Covid Paxlovid.

Wonder if he was one of the lucky ones working at Pfizer who did not choose the jab? Could be he took that special jab not offered to the public similar to the ones offered to Pfizer employees over in Australia. Who knows what is he feeling or thinking. Could be he is suffering and wants to play hard with his blood money before his next infarction. Hard to say. For his sake I hope his conscious is clean and his health is good. Amen.

I anticipate that there will be a market for those patients, who have reached a point, where they are ready to discontinue injections of weight loss meds...but still want to continue with an oral weight loss med.

There’s discussion of the Danuglipron news on the Biotech Values board today.

Dolsten,at age 66 ,with estimated net worth at over $50 million, is unlikely to be looking for challenging new employment..

But the PR did not say Dolsten was retiring, which it surely would have done if that were the case.

"https://seekingalpha.com/news/4123562-pfizer-advances-development-of-once-daily-weight-loss-pill"

Pfizer's ORAL weight loss med IMO, would take significant market share away from the products, which are now on the market...since the competing meds need be taken by weekly INJECTIONS (even if the Pfizer med proves to be slightly less effective)...This would be especially true for patients, who disdain the nuisance and discomfort of injecting themselves on a weekly basis.

'OUSTING' is probably the wrong word...Dolsten is 66 years old...and he probably thought it was time to retire and enjoy his fortune, achieved through being awarded millions of Pfizer shares over his 15 years with the company.

That is the question

A unique breed

Nonetheless

PFE ousts CSO:

https://www.businesswire.com/news/home/20240709792921/en

Who would consent knowing this?
https://petermcculloughmd.substack.com/p/a-pandoras-box-in-the-pharma-lab?publication_id=1119676&post_id=146401978&triggerShare=true&isFreemail=true&r=x7hm&triedRedirect=true
Well, PFE just shoots from the hip. No toxicology studies? OMG
Oh heck, they mean well. Guess I'll just bend over.

Knowing some of the facts that have been exposed....who in their right mind would invest in this company except to squeeze some profit from the pps movement?